Obat Kumur Povidone Iodine sebagai Tindakan Pra-Prosedural untuk Mengurangi Risiko Penularan SARS-CoV-2 dalam Praktik Kedokteran Gigi
DOI:
https://doi.org/10.36408/mhjcm.v7i1A.477Keywords:
SARS-CoV-2, povidone iodine, obat kumur, pra-prosedural, praktik dokter gigiAbstract
Latar Belakang: Kasus COVID-19 menurut WHO per 25 Juli 2020 adalah 15.581.009 kasus terkonfirmasi positif, 635.173 kasus kematian, mencakup 216 negara/wilayah di dunia. Sebuah artikel New York Times menyebut dokter gigi sebagai profesi yang paling rentan terpapar infeksi nosokomial virus SARS-CoV-2. Air liur diketahui mengandung viral load SARS-CoV-2 yang tinggi hingga 1,2×108/per ml. Povidone iodine (PVP-I) menunjukkan aktivitas in vitro terhadap berbagai virus, termasuk SARS-CoV dan MERS. Studi terbaru membuktikan homologi SARS-CoV-2 dengan SARS-CoV mencapai 82%, sehingga ada optimisme bahwa PVP-I juga efektif terhadap SARS-CoV-2 seperti halnya SARS-CoV yang terbukti dapat dinonaktifkan dengan PVP-I.
Tujuan: Mengulas dan melaporkan hasil penelitian terkait penggunaan PVP-I oral terhadap SARS-CoV-2 dalam kasus klinis dan penelitian in vitro.
Metode: Article review dilakukan dengan mengumpulkan jurnal ilmiah secara online menggunakan keyword “povidone iodine”, “povidone iodine covid-19”, “povidone iodine oral rinse”, dan “povidone iodine in dental practice”. Sumber data primer dengan kriteria seleksi data kemudian diskrining. Kriteria inklusi yaitu jurnal yang diterbitkan selama lima tahun terakhir.
Hasil: Hasil studi in vitro dengan uji viral kill time PVP-I 1.0% terhadap sel Vero-E6 yang dilakukan oleh Eggers, et.al. menunjukkan 99.99% efektif terhadap SARS-CoV-2 dalam waktu 30 detik dari kontak. Sedangkan Paranjape, et.al. mengusulkan penggunaan 0.5% PVP-I sebagai desinfeksi oral. Keduanya telah dilakukan uji toksisitas dan hasilnya tidak ada alergi yang dilaporkan.
Simpulan: PVP-I dapat diberikan sebagai upaya pra-prosedural tindakan perawatan gigi yaitu meminta pasien berkumur dengan 1.0% PVP-I 10 ml selama 30 detik sebelum perawatan gigi dimulai. PVP-I telah terbukti sebagai terapi yang aman digunakan sebagai obat kumur.
Kata kunci: SARS-CoV-2, povidone iodine, obat kumur, pra-prosedural, praktik dokter gigi
Abstract
The incidence of COVID-19 has increased in a short time. The COVID-19 case according to WHO as of July 25, 2020 were 15,581,009 positive confirmed cases, 635,173 fatal cases. It occurs in 216 countries/regions in the world. A New York Times article referred dentists as the profession most vulnerable to nosocomial infection of the SARS-CoV-2 virus. Saliva is known to contain a high SARS-CoV-2 viral load of up to 1.2×108/per ml, therefore, the dentist is categorized as high risk subject. Povidone-iodine (PVP-I) shows in vitro activity against various viruses, including SARS-CoV and MERS. Recent studies prove the homology of SARS-CoV-2 with SARS-CoV reaches 82%. With high homology rates, there is optimism that PVP-I is also effective against SARS-CoV-2 as well as SARS-CoV which is proven to be deactivated with PVP-I.
Objective: To review the research results related to the use of oral PVP-I against SARS-CoV-2 in clinical case and in vitro research.
Method: Article review was conducted by collecting scientific journals online using certain keywords: “povidone iodine”, “povidone iodine covid-19”, “povidone iodine oral rinse”, and “povidone iodine in dental practice”. Primary data sources were chosen with data selection criteria and then screened. Inclusion criteria are journals published during the last five years.
Results: In vitro study results with a 1.0% PVP-I viral kill time test of Vero-E6 (American Type Culture Collection) cells, conducted by Eggers, et.al. showed 99.99% virucidal activity against SARS-CoV-2 within 30 seconds of contact. While Paranjape, et.al. propose the use of 0.5% PVP-I as an oral disinfection. Both have been tested for toxicity and no allergic results have been reported.
Conclusion: PVP-I can be safely administered as a pre-procedural in dental treatment, which is intended for use in the patient, i.e to rinse with 1.0% PVP-I 10 ml for 30 seconds before dental treatment. PVP-I has been proven as a safe therapy as a mouthwash.
Keywords: SARS-CoV-2, povidone iodine, mouthwash, pre-procedural, dental practice
Downloads
References
2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et.al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 1–4.
3. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018; 100:163–88.
4. World Health Organization. Coronavirus disease (COVID-19) pandemic [Internet]. World Health Organization. 2020; https://www.who.int/emergencies/diseases/novel-coronavirus-2019
5. Johns Hopkins University and Medicine. Coronavirus Resource Center: John Hopkins University. 2020. https://coronavirus.jhu.edu/map.html
6. Zhu N, Zhang D, Wang W, et.al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727–33.
7. Giacomelli A, Laura Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clinical Infectious Diseases. 2020; 71(15):889. https://doi.org/10.1093/cid/ciaa3300
8. Z. Wu, J.M. McGoogan. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72?314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 10.1001/jama.2020.2648
9. W. Guan, Z. Ni, Y. Hu, et al.Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020; https://www.medrxiv.org/content/10.1101/2020.02.06.20020974v1
10. C. Rothe, M. Schunk, P. Sothmann, et al.Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020; 382: 970-971\
11. Zou, L, Ruan, F, Huang, M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020; 382(12):1177–1179.
12. To KK-W, Tsang OT-Y, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2020; 361: 1319.
13. Gamio, Lazaro. The Workers Who Face the Greatest Coronavirus Risk [Internet]. New York Times. 2020. https://www.nytimes.com/interactive/2020/03/15/business/economy/coronavirus-worker-risk.html
14. World Health Organisation. Interim recommendations on obligatory hand hygiene against transmission of COVID-19. World Health Organization. 2020; https://www.who.int/who-documents-detail/interim-recommendations-on-obligatory-handhygiene-against-transmission-of-covid-19
15. Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther. 2018; 7(2):249–59.
16. Wada H, Nojima Y, Ogawa S, et.al. Relationship between virucidal efficacy and free iodine concentration of povidone-iodine in buffer solution. Biocontrol Sci. 2016; 21(1):21–7. https://doi.org/10.4265/bio.21.21.
17. González-Martín-Moro J, Zarallo-Gallardo J. Iodine povidone. A new paradigm in the treatment of adenoviral conjunctivitis? Povidona yodada. ¿Un nuevo paradigma en el tratamiento de la conjuntivitis adenovírica? Arch Soc Esp Oftalmol. 2019; 94(11):521–2. https://doi.org/10.1016/j.oftal.2019.07.013
18. Silas MR, Schroeder RM, Thomson RB, Myers WG. Optimizing the antisepsis protocol: effectiveness of 3 povidone-iodine 1.0% applications versus a single application of povidone-iodine 5.0. J Cataract Refract Surg. 2017; 43(3):400–4. https://doi.org/10.1016/j.jcrs.2017.01.007
19. World Health Organisation. WHO R&D Blueprint COVID 19 Experimental Treatments [Internet]. World Health Organisation. 2020; https://www.who.int/docs/default-source/coronaviruse/covid-classification-oftreatment-types-rev.pdf
20. Eggers, Maren, et.al. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease. Infect Dis Ther. 2020; https://doi.org/10.1007/s40121-020-00316-3
21. Paranjape, Mandar, et.al. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic. Am J Otolaryngol Journal. 2020; https://doi.org/10.1016/j.amjoto.2020.102618
22. American Dental Association. ADA recommending dentists postpone elective procedures [Internet]. American Dental Association. 2020; https://www.ada.org/en/publications/ada-news/2020-archive/march/ada-recommending-dentists-postponeelective-procedures
23. Urias DS, Varghese M, Simunich T, Morrissey S, Dumire R. Preoperative decolonization to reduce infections in urgent lower extremity repairs. Eur J Trauma Emerg Surg. 2018; 44(5):787–93. https://doi.org/10.1007/s00068-017-0896-1
24. Koerner JC, George MJ, Meyer DR, Rosco MG, Habib MM. Povidone-iodine concentration and dosing in cataract surgery. Surv Ophthalmol. 2018; 63(6):862–8. https://doi.org/10.1016/j.survophthal.2018.05.002
25. Kirk-Bayley J, Challacombe S, Sunkaraneni VS, Combes J. The use of Povidone Iodine nasal spray and mouthwash during the current COVID-19 pandemic may protect healthcare workers and reduce cross infection. http://dx.doi.org/10.2139/ssrn.3563092
26. Mady, Leila J, et.al. Consideration of povidone-iodine as a public health intervention for COVID-19: Utilization as “Personal Protective Equipment” for frontline providers exposed in high-risk head and neck and skull base oncology care. Oral Oncology. 2020; https://doi.org/10.1016/j.oraloncology.2020.104724
27. Produk informasi Betadine Obat Kumur Antiseptik. 2016.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
